Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT02660866

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02660866
Other papers using this trial's data
  • No benefit of vorapaxar on walking performance in patients with intermittent claudication Vascular medicine (London, England), 2022-02 DOI, PubMed 34609939

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02660866. Randomized; quadruple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2019-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Acronym
XLPADTRACE
Condition
Peripheral Arterial Disease
Intervention (Drug)
Placebo + background APT + SMT
Intervention (Drug)
Vorapaxar 2.08 mg/d + background APT + SMT.
Lead sponsor
North Texas Veterans Healthcare System (class: US federal agency)

Record details

Record id
cardio:ct-nct02660866
Content hash
05a5ac189da127f481fb92c521069e359a53456d2136972f389783e228866638